Lebrikizumab, a monoclonal antibody that inhibits an interleukin named IL-13, is especially promising in treatment of this disease. Having been in development by Almirall and Eli Lilly and Company ...

Dermatitis. 2010;21(1):59-60. A 47-year-old female presented for evaluation of a pruritic and painful vulvar dermatitis. The dermatitis began approximately 3 years prior to presentation, shortly ...

Lebrikizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Rhinosinusitis. According to GlobalData, Phase III drugs for Rhinosinusitis have a 75% phase ...

Lebrikizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Nasal Polyps (Nasal Polyposis). According to GlobalData, Phase III drugs for Nasal Polyps (Nasal ...

If the patient has reported a history of steroid use, the first treatment step should be to discontinue the medication's use immediately. However, the patient should be aware that this may result ...

PATIENTS with moderate-to-severe atopic dermatitis who did not initially meet response criteria for lebrikizumab at 16 weeks can still achieve improvements with continued therapy, according to a ...

The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that ...

for mantle cell lymphoma and lebrikizumab for atopic dermatitis, which also rejected by the FDA in a decision earlier this month. Sun Pharma's Taro unit has made a bid to acquire Canadian biotech ...